Group 1 - The company announced a partnership with Yifeng Capital and related parties to establish a seed fund focused on strategic emerging industries, particularly in biomedicine and high-end medical devices [1][2] - The company plans to invest up to 10 million RMB in the fund, which aligns with its long-term development strategy and aims to leverage the expertise of professional investment institutions [1][2] - The investment is expected to enhance the company's investment channels and support sustainable high-quality development without significantly impacting its operations or financial performance [2] Group 2 - The partnership is designed to utilize the management experience and risk control systems of the fund managers, which will help mitigate investment risks and ensure project quality [2] - The investment will not lead to management changes, personnel adjustments, land leasing issues, or create any competition within the industry [2]
昭衍新药(06127)拟出资不超1000万元参与设立生物医药基金